![Søren Weis Dahl](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Søren Weis Dahl
Directeur Général chez
Deck Therapeutics, Inc.
Profil
Søren Weis Dahl currently works at Deck Therapeutics, Inc., as Chief Executive Officer & Director from 2014.
Dr. Dahl also formerly worked at Prophylix AS, as Chief Executive Officer from 2015 to 2019 and Pila Pharma AB, as Director from 2023 to 2024.
Dr. Dahl received his Masters Business Admin degree in 2009 from Copenhagen Business School, doctorate degree in 1997 from Technical University of Denmark, and graduate degree in 1993 from Technical University of Denmark.
Postes actifs de Søren Weis Dahl
| Sociétés | Poste | Début |
|---|---|---|
Deck Therapeutics, Inc.
 Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an acute omega-3 fatty acid therapeutics development company | Directeur Général | 01/01/2014 |
Anciens postes connus de Søren Weis Dahl
| Sociétés | Poste | Fin |
|---|---|---|
| PILA PHARMA AB | Directeur/Membre du Conseil | 01/04/2024 |
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Directeur Général | 01/01/2019 |
Formation de Søren Weis Dahl
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
46
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Copenhagen Business School
 Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Technical University of Denmark
 Technical University of Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Provides prophylactic medicinal product for newborns | Health Technology |
Pila Pharma AB
 Pila Pharma AB BiotechnologyHealth Technology Operates as a clinical stage pharmaceutical company which develops oral anti-diabetic agents | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an acute omega-3 fatty acid therapeutics development company | Health Technology |
